共 50 条
- [32] Re: Intravesical bacillus Calmette-Guerin with Interferon-Alpha versus Intravesical bacillus Calmette-Guerin for Treating Non-Muscle-Invasive Bladder Cancer Editorial Comment [J]. JOURNAL OF UROLOGY, 2018, 199 (03): : 608 - 609
- [34] IMPACT OF POSITIVE BLADDER CANCER FAMILY HISTORY ON THE PROGNOSIS OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUERIN [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E580 - E581
- [35] Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer [J]. Cancer Immunology, Immunotherapy, 2018, 67 : 1371 - 1380
- [38] UTILIZATION OF INITIAL CYSTECTOMY VERSUS INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE MICROPAPILLARY UROTHELIAL CARCINOMA OF THE BLADDER [J]. JOURNAL OF UROLOGY, 2021, 206 : E297 - E297
- [39] Methylation status as a predictor of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor [J]. BIOMEDICAL PAPERS-OLOMOUC, 2017, 161 (02): : 210 - 216
- [40] FAILURE OF BACILLUS CALMETTE-GUERIN THERAPY IN NON-MUSCLE INVASIVE BLADDER CANCER: DEFINITION AND TREATMENT OPTIONS [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (07): : 423 - 433